Peter E. Fecci

Chair and Professor

Duke University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Peter E. Fecci is an Associate Professor at Duke University Medical Center in the United States. His research focuses on glioblastoma immunotherapy, particularly the role of tumor macrophages, as well as the development of prognostic models for intracranial progression following stereotactic radiosurgery. His recent work includes contributions to multicenter validation studies in these areas.

Articles (20)

Radiation necrosis (RN) remains a challenging complication of upfront radiation therapy for both brain metastases and primary tumors. Despite development of an array of advanced imaging modalities to differentiate RN and true tumor progression, tissue diagnosis remains the gold standard. Synergizing artificial intelligence to assist with imaging and intraoperative pathologic diagnosis may represent a fruitful future direction. Similarly, laser interstitial thermal therapy (LITT) is an attractive alternative for RN management when the costs and complications of chronic steroid or bevacizumab are considered. Current evidence suggests an angio-inflammatory cascade is responsible for RN development; tissue-based studies and preclinical modeling are needed to reveal targetable causal mechanisms that may support clinical risk stratification and treatment.

Year:

2026

Purpose: Exhaustion represents a collection of programmed T-cell differentiation states and an important mode of T-cell dysfunction. T-cell progression from progenitor to terminal exhaustion is associated with upregulation of the transcription factor thymocyte selection–associated HMG box (TOX). Our understanding of factors regulating TOX expression and the transition from progenitor to terminal exhaustion, however, remains incomplete. Experimental Design: Single-cell RNA sequencing was used to evaluate the expression of TNF receptors on human and murine tumor-infiltrating CD8 + T cells. Flow cytometry was utilized to assess exhaustion markers and TNF receptors on CD8 + T cells. Bulk RNA sequencing was used to demonstrate the role of TNFR2 on the overall exhaustion profile. Finally, the effect of TNFR2 on the overall antitumor response was established using TNFR2-knockout (KO) mice and an antagonist. Results: We reveal that upregulation of TNFR2 coincides with the gain of phenotypic markers and functions reflective of terminal exhaustion. Loss of TNFR2 affords a novel population of T cells that expresses TIM3 but possesses diminished TOX levels and contains functional characteristics of both progenitor and terminally exhausted cells. TIM3 + TNFR2-KO T cells exhibit reduced exhaustion transcriptional programs and enhanced AP1 pathway signatures. Finally, TNFR2-KO mice demonstrate improved T cell–dependent control of tumor and chronic lymphocytic choriomeningitis infection, whereas pharmacologic antagonism of TNFR2 licenses responses to checkpoint blockade in multiple subcutaneous and intracranial tumor models. Conclusions: Our data place TNFR2 signaling as a potential upstream regulator of TOX expression in T cells and propose TNFR2 antagonism as a novel immunotherapeutic strategy.

Year:

2026

Median time to humane endpoint for subcutaneous (sc) implantation of E0771 and CT2A-Trp2 or intracranial (ic) implantation of CT2A-Trp2 or CT2A. Median survival was not reached in the aTNFR2/aPD1 combination group following intracranial CT2A-Trp2 as 12 out of 20 survived long-term (more than 60 days) and intracranial CT2A (6/10 survived).

Year:

2026

Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.

Year:

2025

Background: Glioblastoma (GBM) remains the most aggressive primary brain tumor with limited treatment options. The immunosuppressive tumor microenvironment (TME), largely shaped by tumor-associated macrophages (TAMs), represents a significant barrier to effective immunotherapy. Objective: This review aims to explore the role of TAMs within the TME, highlighting the phenotypic plasticity, interactions with tumor cells, and potential therapeutic targets to enhance anti-tumor immunity. Findings: TAMs constitute a substantial portion of the TME, displaying functional plasticity between immunosuppressive and pro-inflammatory phenotypes. Strategies targeting TAMs include depletion, reprogramming, and inhibition of pro-tumor signaling pathways. Preclinical studies show that modifying TAM behavior can shift the TME towards a pro-inflammatory state, enhancing antitumor immune responses. Clinical trials investigating inhibitors of TAM recruitment, polarization, and downstream signaling pathways reveal promising yet limited results, necessitating further research to optimize approaches. Conclusions: Therapeutic strategics targeting TAM plasticity through selective depletion, phenotypic reprogramming, or modulation of downstream immunosuppressive signals represent promising avenues to overcome GBM-associated immunosuppression. Early clinical trials underscore their safety and feasibility, yet achieving meaningful clinical efficacy requires deeper mechanistic understanding and combinatorial approaches integrating macrophage-direct therapies with existing immunotherapeutic modalities.

Year:

2025

Background: Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess the relationship between atopy and survival or reduced BrM cumulative incidence (CI) in melanoma. Methods: This retrospective study was conducted in individuals (≥66 years) in linked Surveillance, Epidemiology, and End Results and Medicare data. History of atopy diagnosed prior to melanoma was ascertained using International Classification of Diseases-9/10 codes. Associations between atopy, CI of BrM, and overall survival were assessed using cox proportional hazards models to estimate hazard ratios and P values. Results: A total of 23,508 cutaneous melanoma cases were identified. Overall, 6.1% developed BrM, and 38% had history of atopy. Atopy was associated with an 18% decrease in death (P < 0.001). Among those without metastasis at diagnosis, atopy decreased BrM CI by 16% (P = 0.006). Among those with metastasis at diagnosis (any site), only those who received checkpoint inhibitors had a suggestive but nonsignificant survival with atopy. Conclusions: Atopy confers improved survival and decreased BrM CI. History of atopy in the elderly may identify those with more robust immune function that may be more responsive to treatment. Impact: Elderly individuals with prior diagnosis of atopy had significantly improved survival and decreased incidence of BrM as compared with individuals without atopy. This suggests that history of atopy may identify a subgroup within melanoma with improved response to treatment and a more robust immune system.

Year:

2025

Year:

2025

Year:

2025

Background Stereotactic radiosurgery (SRS) is widely used for managing brain metastases (BMs), but an adverse effect, radionecrosis, complicates post‐SRS management. Differentiating radionecrosis from tumor recurrence non‐invasively remains a major clinical challenge, as conventional imaging techniques often necessitate surgical biopsy for accurate diagnosis. Machine learning and deep learning models have shown potential in distinguishing radionecrosis from tumor recurrence. However, their clinical adoption is hindered by a lack of explainability, limiting understanding and trust in their diagnostic decisions. Purpose To utilize a novel neural ordinary differential equation (NODE) model for discerning BM post‐SRS radionecrosis from recurrence. This approach integrates image‐deep features, genomic biomarkers, and non‐image clinical parameters within a synthesized latent feature space. The trajectory of each data sample towards the diagnosis decision can be visualized within this feature space, offering a new angle on radiogenomic data analysis foundational for AI explainability. Methods By hypothesizing that deep feature extraction can be modeled as a spatiotemporally continuous process, we designed a novel model based on heavy ball NODE (HBNODE) in which deep feature extraction was governed by a second‐order ODE. This approach enabled tracking of deep neural network (DNN) behavior by solving the HBNODE and observing the stepwise derivative evolution. Consequently, the trajectory of each sample within the Image‐Genomic‐Clinical (I‐G‐C) space became traceable. A decision‐making field ( F ) was reconstructed within the feature space, with its gradient vectors directing the data samples’ trajectories and intensities showing the potential. The evolution of F reflected the cumulative feature contributions at intermediate states to the final diagnosis, enabling quantitative and dynamic comparisons of the relative contribution of each feature category over time. A velocity curve was designed to determine key intermediate states (locoregional ∇ F = 0) that are most predictive. Subsequently, a non‐parametric model aggregated the optimal solutions from these key states to predict outcomes. Our dataset included 90 BMs from 62 NSCLC patients, and 3‐month post‐SRS T1+c MR image features, seven NSCLC genomic features, and seven clinical features were analyzed. An 8:2 train/test assignment was employed, and five independent models were trained to ensure robustness. Performance was benchmarked in sensitivity, specificity, accuracy, and ROC AUC , and results were compared against (1) a DNN using only image‐based features, and (2) a combined “I+G+C” features without the HBNODE model. Results The temporal evolution of gradient vectors and potential fields in F suggested that clinical features contribute the most during the initial stages of the HBNODE implementation, followed by imagery features taking dominance in the latter ones, while genomic features contribute the least throughout the process. The HBNODE model successfully identified and assembled key intermediate states, exhibiting competitive performance with an ROC AUC of 0.88 ± 0.04, sensitivity of 0.79 ± 0.02, specificity of 0.86 ± 0.01, and accuracy of 0.84 ± 0.01, where the uncertainties represent standard deviations. For comparison, the image‐only DNN model achieved an ROC AUC of 0.71 ± 0.05 and sensitivity of 0.66 ± 0.32 ( p = 0.086), while the “I+G+C” model without HBNODE reported an ROC AUC of 0.81 ± 0.02 and sensitivity of 0.58 ± 0.11 ( p = 0.091). Conclusion The HBNODE model effectively identifies BM radionecrosis from recurrence, enhancing explainability within XAI frameworks. Its performance encourages further exploration in clinical settings and suggests potential applicability across various XAI domains.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Collaborators (26)

Saritha Krishna Lalitha Kumari Krishnan Nair

Assistant Adjunct Professor

University of California, San Francisco

UNITED STATES
View details

scott floyd

Associate Professor

Duke University

UNITED STATES
View details

Alexa Bramall

Duke University

UNITED STATES
View details

Christopher Mariani

Professor of Veterinary Neurology & Neurosurgery

North Carolina State University

UNITED STATES
View details

Mustafa Khasraw

Professor

Duke University

UNITED STATES
View details

Anoop Patel

Associate Professor

Duke University

UNITED STATES
View details

Katayoun Ayasoufi

Assistant Professor

Duke University

UNITED STATES
View details

Shawn L. Hervey‐Jumper

Professor

University of California, San Francisco

UNITED STATES
View details

Carey Anders

Assistant Director of Clinical Research

Duke University

UNITED STATES
View details

Michael W Nolan

Professor

North Carolina State University

UNITED STATES
View details

Chuan-Yuan Li

Professor and Vice Chair for Research

Duke University School of Medicine

UNITED STATES
View details

Matthew Foster

Duke University

UNITED STATES
View details

Jordan M. Komisarow

Duke University

UNITED STATES
View details

Quinn Ostrom

Assistant Professor

Duke University School of Medicine

UNITED STATES
View details

Laura Alder

Duke University

UNITED STATES
View details

Kyle Walsh

Duke University

UNITED STATES
View details

James Herndon

Professor

Duke University Medical Center

UNITED STATES
View details

Jill S Barnholtz-Sloan

Duke University School of Medicine

UNITED STATES
View details

C. Rory Goodwin

Duke University Medical Center

UNITED STATES
View details

Daniel Wilkinson

Assistant Research Professor

University of Colorado Cancer Center

UNITED STATES
View details

Todd Hollon

University of Michigan

UNITED STATES
View details

April K.S. Salama

Duke University Medical Center

UNITED STATES
View details

Annick Desjardins

Professor of Neurosurgery and Neurology

Duke University

UNITED STATES
View details

Simon G. Gregory

Professor

Duke University

UNITED STATES
View details

ROGER MCLENDON

Professor

Duke University School of Medicine

UNITED STATES
View details

Beth Shaz

Duke University

UNITED STATES
View details